I met him as a patient with a back condition, not a cardiac patient. A 70-year-old man who looked like he had outrun aging through sheer willpower and a well-worn bicycle. He rode more than a hundred miles a week, had the resting heart rate of a seasoned athlete, and carried himself with the kind of confidence that comes from a lifetime of good health. His only complaint was lower-back pain, which is how he ended up in my exam room.
Nothing about him suggested heart disease. Nothing suggested he was about to become a cautionary tale about the cost of modern medicine.
But one afternoon, he and his wife decided to get coronary calcium scores together. It was her idea, one of those shared preventive health errands couples do without expecting anything in return. Her score was normal. His was over 600.
That number changed the trajectory of his life.
Suddenly, this man who had never taken more than an occasional ibuprofen was pulled into a network of cardiovascular diagnostics. Stress testing, echocardiography, advanced lipid panels, and eventually a cardiac MRI. The MRI raised suspicion for an infiltrative cardiomyopathy. A cardiac biopsy followed.
The biopsy confirmed wild-type transthyretin amyloid cardiomyopathy (ATTR), a disease he had never heard of, a disease that caused him no symptoms, and a disease that, until recently, we could diagnose but not treat.
And then came the treatment plan: a newly approved injection therapy costing nearly $500,000 per year.
His insurance approved it, and treatment began. I was glad to hear this, since I knew full well that these costly treatment decisions do not end this way. His story made me wrestle with the ethical implications of a system that can deliver a half-million-dollar therapy to one patient while denying it to another with the same diagnosis.
I am not a cardiologist, but I can understand the excitement around ATTR therapies. For years, this disease was a slow, silent thief of cardiac function. Now we have medications that stabilize transthyretin, slow progression, and preserve quality of life. From a scientific standpoint, this is extraordinary.
From a societal standpoint, it is deeply troubling.
The price tags are staggering. Tafamidis, the most commonly prescribed ATTR-CM drug, costs around $225,000 to $268,000 per year. Newer RNA interference therapies, patisiran, inotersen, and vutrisiran, range from $442,000 to nearly $500,000 annually. These are not one-time gene therapies. These are lifelong treatments. A patient diagnosed in their seventies could easily accumulate well over a million dollars in medication costs alone.
And yet, for my patient, the approval came through without resistance. He was grateful. He felt fortunate. He told me he had no idea such a disease existed, let alone that he might have it.
But as he spoke, I thought of other patients, patients with symptoms, with heart failure, with declining function, who cannot access the same therapy because their insurance denies it or because they fall into the financial purgatory of being “not poor enough” for assistance and “not wealthy enough” to pay out of pocket.
Science is advancing. The access is not. I also fully understand the reality of the cost for new drug development. Pharmaceutical companies spend billions of dollars on new drug research, clinical development, clinical studies, and drug manufacturing, under rigorous regulatory requirements that both ensure the safety of new drugs and raise the costs of bringing them to market. In addition, of every 10 drugs under development, only a handful will make it commercially, and that after the patent coverage clock has been well underway. Companies must recoup these development costs before even beginning to generate profits for their investors. That is just the financial reality of developing miracle-drug alternatives for intractable diseases.
Yet, my patient’s example raises uncomfortable but necessary questions. What does it mean to diagnose a disease when the treatment is financially inaccessible to many?
His calcium score, an incidental finding, opened the door to a diagnosis that carries a treatment cost equivalent to a luxury home. He did not expect to get a diagnosis. He had no symptoms. He had no reason to suspect anything was wrong. Yet he now receives a therapy that many symptomatic patients cannot obtain.
This is not a criticism of him. It is simply pointing to a system that rewards timing, insurance design, and happenstance over clinical need.
We encourage screening because early detection saves lives. But early detection only matters if treatment is accessible. Otherwise, we risk widening disparities rather than closing them.
As physicians, we celebrate scientific progress. But we also feel the moral tension of practicing in a system where access to life-altering therapy depends on insurance algorithms rather than medical judgment. I have seen patients deteriorate while waiting for insurance appeals. I have seen families forced to choose between financial ruin and medical hope. I have seen clinicians caught between recommending the best therapy and knowing it may be unattainable.
This is the silent moral dilemma of modern medicine: knowing what could help a patient, yet being unable to offer it.
We talk about health equity as a policy goal without acknowledging the painful realities of its implications. But cases like this expose the gap between rhetoric and reality. My patient’s access to therapy was determined by his insurance plan, his wife’s decision to get a calcium score, and the willingness of the system to approve a half-million-dollar medication. Meanwhile, another patient with the same disease may be denied coverage because their insurer interprets the evidence differently or because they live in a different state.
This is not equity. It is a lottery.
The ATTR therapy is not unique. It is simply the latest example of a broader trend: breakthrough treatments priced at levels that strain the boundaries of ethical practice. We need a national conversation about the cost of innovation, one that acknowledges that a therapy priced at $500,000 a year cannot be separated from the need and right to receive the medication, if you have the need and, in particular, if you are insured.
Because right now, cost is the silent determinant of care.
I did not diagnose his cardiomyopathy. I did not prescribe his therapy. I simply treated his back pain. But I witnessed the emotional and ethical ripple effects of a system that can deliver extraordinary science at extraordinary cost.
His story is not about ATTR. It is about the widening gap between what medicine can do and what patients can access.
Until we confront the cost of care with the same urgency that we pursue scientific breakthroughs, we will continue to practice two kinds of medicine: one for those who can afford it, and one for those who cannot.
And that, more than any diagnosis, is the real disease we need to treat.
Francisco M. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine and can be reached at Florida Spine Institute and Wellness.
Dr. Torres was born in Spain and grew up in Puerto Rico. He graduated from the University of Puerto Rico School of Medicine. Dr. Torres performed his physical medicine and rehabilitation residency at the Veterans Administration Hospital in San Juan before completing a musculoskeletal fellowship at Louisiana State University Medical Center in New Orleans. He served three years as a clinical instructor of medicine and assistant professor at LSU before joining Florida Spine Institute in Clearwater, Florida, where he is the medical director of the Wellness Program.
Dr. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine. He is a prolific writer and primarily interested in preventative medicine. He works with all of his patients to promote overall wellness.
